BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
March 12, 2024 07:00 ET | BioCardia, Inc.
Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
November 14, 2023 07:15 ET | BioCardia, Inc.
SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
September 06, 2023 07:15 ET | BioCardia, Inc.
SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
July 24, 2023 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
June 08, 2023 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...